67th ASH Annual Meeting and Exposition

ASH 2025: Spotlighting the Latest Research, Therapies and Practice Implications for Community Oncology Practices  

More than 30,000 hematology professionals from around the world gathered in Orlando earlier this month for the 67^th ASH Annual Meeting and Exposition. Attendees explored new research, connected with leading clinicians and learned about emerging therapies and practice innovations aimed at improving patient care.

This year’s meeting featured 8,200 abstracts and hundreds of sessions and exhibits. Community oncology providers now bring this knowledge back to their practices, allowing patients to benefit from the latest advancements close to home.

Key Research Themes

ASH 2025 received a record number of abstract submissions spanning bleeding and clotting disorders, bone marrow failure syndromes, genetic and immune disorders, hemoglobinopathies, infectious diseases, lymphoid and myeloid malignancies, and metabolic diseases.

Multiple physicians from American Oncology Network partner practices presented research and co-authored accepted abstracts:

Sunil Babu, MD – Fort Wayne Medical Oncology and Hematology

• Co-authored: Promising Response Rates and Manageable Safety with Mosunetuzumab Plus Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma.

 Ruemu E. Birhiray, MD – Hematology Oncology of Indiana

• Co-authored:
  • Patient-Reported Outcomes and Actigraphy Following In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma
  • Beyond Approval: Lymphoma Drugs and Real-World Representation
  • Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data
• Chaired:
  • Bringing Emerging Treatments to All Patients: Strategies for Implementing T-Cell Redirection Therapies in Community Oncology Practices

Ralph V. Boccia, MD, FACP – The Center for Cancer and Blood Disorders

• Co-authored:
  • Optimizing Adherence to Oral CLL Therapies in Community Oncology Centers: Key Findings from a Quality Improvement Initiative
  • Outpatient Administration of Epcoritamab Monotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by Race and Ethnicity

• Presented: Bringing Emerging Treatments to All Patients: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices

David Kahn, MD, MPH – Desert Hematology Oncology

• Co-authored: Optimizing Adherence to Oral CLL Therapies in Community Oncology Centers: Key Findings from a Quality Improvement Initiative

Brian Mulherin, MD – Hematology Oncology of Indiana

• Co-authored:
  • Asciminib (ASC) in Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
  • Real-World Comparison of Treatment Outcomes Between BCL2i and 2nd Generation BTKi Therapy in First-Line CLL Patients
  • Initial Performance of Pirtobrutinib: Real-World Outcomes Among CLL Patients After Prior Covalent-BTKi and BCL2i Use
  • Evaluation of Real-World Outcomes Among CLL Patients Based on Sequencing of BTKi and BCL2i Therapies

Taral Patel, MD – Zangmeister Cancer Center

• Presented and co-authored:
  • Real-World Comparison of Treatment Outcomes Between BCL2i and 2nd Generation BTKi Therapy in First-Line CLL Patients
  • Initial Performance of Pirtobrutinib: Real-World Outcomes Among CLL Patients After Prior Covalent-BTKi and BCL2i Use
  • Evaluation of Real-World Outcomes Among CLL Patients Based on Sequencing of BTKi and BCL2i Therapies

Emerging Therapies

Sessions highlighted advances in bispecific antibodies, CAR T-cell therapies and real-world data informing treatment decisions in community settings. Presentations on immunotherapies—including evolving strategies to expand CAR T-cell use beyond CD19—offered insights that may improve patient selection, toxicity management and coordination with tertiary centers.

Practice Implications for Community Oncology

A range of sessions focused on incorporating new data into clinical pathways, strengthening partnerships between community and academic providers, and improving access to clinical trials. One highlight examined how community-based and academic hematologists can collaborate to increase trial participation—a key component of expanding access to innovative therapies.

Health equity was also a major theme. Discussions aligned closely with AON’s mission to make high-quality, patient-centered cancer care accessible in the communities where patients live and work. Sessions addressed genetic diversity in precision medicine research and practical strategies to overcome language and cultural barriers that can affect treatment access and outcomes.

Keeping Pace

The breadth of research presented at ASH 2025 underscores how quickly hematology continues to advance. AON’s partner practice physicians continue to lead the way—sharing research and engaging with hematology professionals from around the world—to ensure that oncology patients always have access to cutting-edge therapies close to home.